🟢 Moderna is trading 4.3% up in pre-market after FDA approval of mFLUSIVA

Moderna is trading at $61.70, up +4.28%, after the FDA approved mFLUSIVA, its first mRNA-based seasonal flu vaccine.

• The approval covers adults aged 50 and older: traditional authorization for ages 50–64 and accelerated approval for those 65 and older.
• No separate August 10 company announcement was identified; the pre-market move appears to reflect continued follow-through from the August 5 approval and upcoming commercial launch.